<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="monograph" /><meta name="keywords" content="Fondaparinux; Arixtra; Fondaparinux" /><meta name="IX" content="Arixtra; Fondaparinux" /><meta name="IXM" content="Fondaparinux" /><title>FONDAPARINUX SODIUM: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="112795.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="112795.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=112795.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="1002.htm">2 Cardiovascular system</a> &gt; <a href="2760.htm">2.8 Anticoagulants and protamine</a> &gt; <a href="2761.htm">2.8.1 Parenteral anticoagulants</a> &gt; <a href="112794.htm">Fondaparinux</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="112794.htm" title="Previous: Fondaparinux">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="112796.htm#_112796" title="Next: Arixtra®">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a302012.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Fondaparinux Sodium</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Blood Formation, Coagulation, and Thrombosis 20:00 &gt; Antithrombotic Agents 20:12 &gt; Anticoagulants 20:12.04 &gt; Direct Factor Xa Inhibitors 20:12.04.14</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/22570-b.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Fondaparinux</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: F &gt; Interactions of Fondaparinux</p></div></li></ul><ul><li><h3>British National Formulary (3)</h3></li><li><a href="112794.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Fondaparinux</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 2 Cardiovascular system &gt; 2.8 Anticoagulants and protamine &gt; 2.8.1 Parenteral anticoagulants</p></div></li><li><a href="112796.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Arixtra®</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 2 Cardiovascular system &gt; 2.8 Anticoagulants and protamine &gt; 2.8.1 Parenteral anticoagulants &gt; Fondaparinux &gt; FONDAPARINUX SODIUM</p></div></li><li><a href="200276.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Fondaparinux</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; Appendix 4 Intravenous additives &gt; Use of table &gt; Table of drugs given by intravenous infusion</p></div></li></ul><ul><li><h3>Clarke's Analysis of Drugs and Poisons</h3></li><li><a href="http://www.medicinescomplete.com/mc/clarke/2010/CLK-TD-c153-mn0001.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Fondaparinux Sodium</a><div class="breadcrumb"><p><strong>Clarke's Analysis of Drugs and Poisons</strong> &gt; Monographs &gt; Alphabetically &gt; F</p></div></li></ul><ul><li><h3>Injectable Drugs Guide</h3></li><li><a href="http://www.medicinescomplete.com/mc/idg/2010/f11-mn0001.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Fondaparinux sodium</a><div class="breadcrumb"><p><strong>Injectable Drugs Guide</strong> &gt; Injectable Drugs Guide &gt; Monographs &gt; F</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/20172-x.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Fondaparinux Sodium</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Cardiovascular Drugs &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/04232.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Fondaparinux Sodium</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; F &gt; FO</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E2E0E16E3E0R0D842.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Fondaparinux</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; F</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1 id="_112795">FONDAPARINUX SODIUM</h1><?highlighter on?><div id="pC" class="jN"><div class="cAF"><h2>Indications</h2> <p class="cAF">prophylaxis of venous thromboembolism in medical patients immobilised
because of acute illness, and patients undergoing major orthopaedic
surgery of the hip or leg, or abdominal surgery; treatment of deep-vein
thrombosis, superficial-vein thrombosis, and pulmonary embolism; treatment
of unstable angina or non-ST-segment elevation myocardial infarction;
treatment of ST-segment elevation myocardial infarction</p></div><div class="cAF"><h2>Cautions</h2> <p class="cAF">bleeding disorders, active gastro-intestinal ulcer disease; recent intracranial haemorrhage; brain, spinal, or ophthalmic surgery; spinal or epidural anaesthesia (risk of spinal haematoma—avoid if using treatment doses); risk of catheter thrombus during percutaneous coronary intervention; low body-weight; elderly
patients; concomitant use of drugs that
increase risk of bleeding</p></div><div class="cAF"><h2>Contra-indications</h2> <p class="cAF">active bleeding; bacterial endocarditis</p></div><div class="cAF"><h2>Hepatic impairment</h2> <p class="cAF">caution in severe impairment (increased risk of bleeding)</p></div><div class="cAF"><h2>Renal impairment</h2> <p class="cAF">increased risk of bleeding; for <i>treatment of
acute coronary syndromes</i> avoid if eGFR less than 20 mL/minute/1.73 m<sup>2</sup>; for <i>treatment of venous thromboembolism</i> use with caution if eGFR 30–50 mL/minute/1.73 m<sup>2</sup>, avoid
if eGFR less than 30 mL/minute/1.73 m<sup>2</sup>; for <i>prophylaxis
of venous thromboembolism</i> and <i>treatment of superficial-vein
thrombosis</i> reduce dose to 1.5 mg daily if eGFR 20–50 mL/minute/1.73 m<sup>2</sup>, avoid if eGFR less than 20 mL/minute/1.73 m<sup>2</sup></p></div><div class="cAF"><h2>Pregnancy</h2> <p class="cAF">manufacturer advises avoid unless potential benefit
outweighs possible risk—no information available</p></div><div class="cAF"><h2>Breast-feeding</h2> <p class="cAF">present in milk in <i>animal</i> studies—manufacturer
advises avoid</p></div><div class="cAF"><h2>Side-effects</h2> <p class="cAF">bleeding, purpura, anaemia; <i>less commonly</i> gastro-intestinal disturbances, oedema, hepatic impairment, chest
pain, dyspnoea, thrombocytopenia, thrombocythaemia, rash, pruritus; <i>rarely</i> hypotension, flushing, cough, vertigo, dizziness,
anxiety, drowsiness, confusion, headache, hypokalaemia, hyperbilirubinaemia,
injection-site reactions; also reported atrial fibrillation, tachycardia,
and pyrexia</p></div><div class="cAF"><h2>Dose</h2> <ul class="cBF"><li><p class="cQ">Prophylaxis of venous thromboembolism after surgery, <span class="cU">by subcutaneous injection</span>, 2.5 mg 6 hours after surgery then
2.5 mg once daily; <span class="cAK">child</span> under 17 years
not recommended</p></li><li><p class="cQ">Prophylaxis of venous thromboembolism in medical patients, <span class="cU">by subcutaneous injection</span>, 2.5 mg once daily; <span class="cAK">child</span> under 17 years not recommended</p></li><li><p class="cQ">Treatment of superficial-vein thrombosis, <span class="cU">by subcutaneous
injection</span>, <span class="cAK">adult</span> body-weight
over 50 kg, 2.5 mg once daily for at least 30 days (max. 45 days if
high risk of thromboembolic complications); treatment should be stopped
24 hours before surgery and restarted at least 6 hours post operatively; <span class="cAK">child</span> under 17 years not recommended</p></li><li><p class="cQ">Unstable angina and non-ST-segment elevation myocardial
infarction, <span class="cU">by subcutaneous injection</span>, 2.5 mg once
daily for up to 8 days (or until hospital discharge if sooner); treatment
should be stopped 24 hours before coronary artery bypass graft surgery
(where possible) and restarted 48 hours post operatively; <span class="cAK">child</span> under 17 years not recommended</p></li><li><p class="cQ">ST-segment elevation myocardial infarction, initially <span class="cU">by intravenous injection</span> or <span class="cU">infusion</span>, 2.5 mg
for first day, thereafter <span class="cU">by subcutaneous injection</span> 2.5 mg once daily for up to 8 days (or until hospital discharge
if sooner); treatment should be stopped 24 hours before coronary artery
bypass graft surgery (where possible) and restarted 48 hours post
operatively; <span class="cAK">child</span> under 17 years not
recommended</p></li><li><p class="cQ">Treatment of deep-vein thrombosis and of pulmonary embolism, <span class="cU">by subcutaneous injection</span>, <span class="cAK">adult</span> body-weight under 50 kg, 5 mg every 24 hours; body-weight 50–100 kg,
7.5 mg every 24 hours; body-weight over 100 kg, 10 mg every 24 hours; <span class="cAK">child</span> under 17 years not recommended</p><p class="cQ"><b>Note</b> An oral anticoagulant (usually warfarin, <a title="BNF:sub-section: Oral anticoagulants" href="2791.htm#_2791">section 2.8.2</a>) is started at the same time
as fondaparinux (fondaparinux should be continued for at least 5 days
and until INR ≥2 for at least 24 hours)</p></li></ul></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="112796.htm#_112796" title="Arixtra®">Arixtra®</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="112794.htm">Previous: Fondaparinux</a> | <a class="top" href="112795.htm#">Top</a> | <a accesskey="]" href="112796.htm#_112796" title="Arixtra®">Next: Arixtra®</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>